Improvement of visual acuity based on optical coherence tomography patterns following intravitreal bevacizumab treatment in patients with diabetic macular edema

International Journal of Ophthalmology

Volumn 7, Issue 2, 2014, Pages 251-255

  Cheema, Haider R ^a   Habash, Ahmed Al ^b   Al Askar, Essam ^c  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b IMAM ABDULRAHMAN BIN FAISAL UNIVERSITY   (Saudi Arabia)

^c Dhahran Eye Specialist Hospital   (Saudi Arabia)

Author keywords

Bevacizumab; Diabetic macular edema; Intravitreal injection; Optical coherence tomography

Indexed keywords

EID: 84899828352     PISSN: 22223959     EISSN: 22274898     Source Type: Journal    
DOI: 10.3980/j.issn.2222-3959.2014.02.11     Document Type: Article

References (19)

1. Romero-Aroca P. Current status in diabetic macular edema treatments. World J Diabetes. 2013;4(5):l65-l69. [PMCfree article] [PubMed]
2. Hall HN,Chinn DJ, Sinclair A, Styles CJ. Epidemgy of blindness attributable to diabetes in Scotland: changeover 20 years in a defined population. Diabet Med. 2013;3o(ll):l349-l354. [PubMed]
3. Petrella RJ, Biuin J, Davies B, Barbeau M. Prevalence, demographics, andtreatment characteristics of visual impairment due to diabetic macular edema in a representative Canadian cohort. JOphthalmol. 2012;2012:159167. [PMCfree article] [PubMed]
4. Ciulla TA, Harris A, Latkany P, Piper HC, ArendO, Garzozi H, Martin B. Ocular perfusn abnormalities in diabetes. Acta Ophthalmol Scand. 2002;8o(5):468-477. [PubMed]
5. Thomas BJ, Shienbaum G, Boyer DS, Flynn HW., Jr. Evolving strategies in the management of diabetic macular edema: clinical trials andcurrent management. Can JOphthalmol. 2013;48(l):22-3O. [PubMed]
6. Stewart MW. Anti-vascular endothelial growth factor drug treatment of diabetic macular edema: the evolution continues. Curr Diabetes Rev. 2012;8(4):237-246. [PubMed]
7. Massin P, Bandel10F, Garweg JG, Hansen LL, Harding SP, Larsen M, Mitchell P, Sharp D,Wolf-Schnurrbusch UE, Gekkieva M, Weichselberger A, Wolf S. Ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, contred, double-masked, multicenter phase II study. Diabetes Care. 2010;33(ll):2399-2405. [PMCfree article] [PubMed]
8. Diabetic Retinopathy Clinical Research Network. Scott IU, Edwards AR, Beck RW, Bressler NM, Chan CK, Elman MJ, Friedman SM, Greven CM, Maturi RK, Pieramici DJ, Shami M, Singerman LJ, Stockdale CR. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmogy. 2007;ll4(10):l86o-l867. [PMCfree article [PubMed]
9. Areva JF, Sanchez JG, Wu L, Mai a M, Alezzandrini AA, BritoM, BonafonteS, Lujan S, Diaz-Lis M, RestrepoN, Rodriguez FJ, Udaondo-Mirete P, Pan-American C011aborative Retina Study Group Primary intravitreal bevacizumab for diffuse diabetic macular edema: the Pan-American C011aborative Retina Study Group at 24 months. Ophthalmogy. 2009;ll6(8):l488-l497. [PubMed]
10. Al-Shaaln FF, Bakrman MA, Ibrahim AM, Aljoudi AS. Prevalence and causes of visual impairment among Saudi adults attending primary health care centers in northern Saudi Arabia. Ann Saudi Med. 2011;3l(5):473-48o. [PMCfree article] [PubMed]
11. G10ver SJ, Burgess PI, Cohen DB, Harding SP, Hofland HW, Zijlstra EE, Allain TJ. Prevalence of diabetic retinopathy, cataract andvisual impairment in patients with diabetes in sub-Saharan Africa. Br JOphthalmol. 2012596(2) :15 6-161. [PubMed]
12. PesiniL, Hull CC, Boyce JF, McHugh D, Stanford MR, Marshall J. Optical coherence tomography may be used to predict visual acuity in patients with macular edema. Invest Ophthalmol Vis Sci. 2011;52(5):274l-2748. [PubMed]
13. Kim BY, Smith SD, Kaiser PK. Optical coherence torn ographic patterns of diabetic macular edema. Am JOphthalmol. 2006;142(3):405-412. [PubMed]
14. Kim M, LeeP, Kim Y, Yu SY, Kwak HW. Effect of intravitreal bevacizumab based on optical coherence tomography patterns of diabetic macular edema. Ophthalmogica. 2011;226(3):l38-l44. [PubMed]
15. 15-Wu PC, Lai CH, Chen CL, KuoCN. Optical coherence tornographic patterns in diabetic macula edema can predict the effects of intravitreal bevacizumab injection as primary treatment. JOcul Pharmacol Ther. 2012;28(l):59-64. [PubMed]
16. Koytak A, Altinisik M, Sogutlu Sari E, Artunay O, Umurhan Akkan JC, Tuncer K. Effect of a single intravitreal bevacizumab injection on different optical coherence torn ographic patterns of diabetic macular oedema. Eye (nd) 2013;27(6):7l6-72l. [PMCfree article] [PubMed]
17. Suh MH, SeoJM, Park KH, Yu HG. Associations between macular findings by optical coherence tomography and visual outcomes after epiretinal membrane removal. Am JOphthalmol. 2009;l47(3):473-48o. [PubMed]
18. SanoM, Shimoda Y, Hashimoto H, Kishi S. Restored photoreceptor outer segment and visual recovery after macular hole csure. Am JOphthalmol. 20105149(2) 1284-290. [PubMed]
19. Shin HJ, Lee SH, Chung H, Kim HC. Association between photoreceptor integrity and visual outcome in diabetic macular edema. Graefes Arch Clin Exp Ophthalmol. 2012;250(l):6l-70. [PubMed]